Ruthenium (Ru) complexes are developed as latent emissive photosensitizers for cancer
and pathogen photodiagnosis and therapy. Nevertheless, most existing Ru complexes are …

Ruthenium complexes are emerging as potential complements to platinum drugs. They also
show promise as photo-diagnostic and therapeutic agents. However, most ruthenium …

Although Ru (II)-based agents are expected to be promising candidates for substituting Pt-
drug, their in vivo biomedical applications are still limited by the short excitation/emission …

Despite the success of emissive Ruthenium (Ru) agents in biomedicine, problems such as
the visible‐light excitation/emission and single chemo‐or phototherapy modality still hamper …

Although metallacycle-based photosensitizers have attracted increasing attention in
biomedicine, their clinical application has been hindered by their inherent dark toxicity and …

As an effective and noninvasive treatment of various diseases, photodynamic therapy (PTD)
relies on the combination of light, a photosensitizer, and oxygen to generate cytotoxic …

There has been emerging interest in the exploitation of the photophysical and
photochemical properties of transition metal complexes for diagnostic and therapeutic …

Bacterial infection is one of the greatest threats to public health. In vivo real‐time monitoring
and effective treatment of infected sites through non‐invasive techniques, remain a …

Although metallacycle‐based supramolecular photosensitizers (PSs) have attracted
increasing attention in biomedicine, their clinical translation is still hindered by their inherent …

Combining the best attributes of organic photosensitizers with those of coordination
complexes is an elegant way to achieve prolonged excited state lifetimes in Ru (II) dyads …